Lupin Q3 Results: Profit Rises 40%, Beats Estimates
Lupin's net profit rose 39.5% year-on-year to Rs 855 crore in the quarter ended Dec. 31, 2024.
Lupin Ltd.'s consolidated net profit rose in the third quarter of the financial year, beating analysts' estimates.
Net profit rose 39.5% year-on-year to Rs 855 crore in the quarter ended Dec. 31, 2024, in comparison to Rs 613 crore in the year-ago period, according to an exchange filing on Wednesday. Analysts tracked by Bloomberg had estimated a profit of Rs 792.6 crore.
Lupin Q3 FY25 Earnings Highlights (Consolidated, YoY)
Revenue up 11% to Rs 5,768 crore versus Rs 5,197 crore (Bloomberg estimate: Rs 5,686 crore).
Ebitda up 33.6% to Rs 1,366 crore versus Rs 1,022 crore (Bloomberg estimates: Rs 1,282.8 crore).
Margin expands to 23.7% versus 19.7% (Estimate: 22.6%).
Net profit up 39.5% to Rs 855 crore, against Rs 613 crore. (Estimate: Rs 792.6 crore).
The rise in revenue was led by building scale in new products and were aided by higher PLI and export benefits.
North America sales grew 12.3% year-on-year, accounting for 38% of global sales. The sequential growth in US sales was led by higher market share in Albuterol, as well as, sales ramp-up of both 25 mg and 50 mg versions of generic Myrbetriq.
India sales grew 11.9% year-on-year, led by strong growth in diabetes portfolio and accounted for 34% of global sales. Lupin launched 11 brands across diabetes, neuro/CNS in India.
Shares of Lupin closed 4.69% lower at Rs 2,067.6 apiece on the NSE, compared to a 1.32% decline in the benchmark Nifty 50.
